JP2017500305A5 - - Google Patents

Download PDF

Info

Publication number
JP2017500305A5
JP2017500305A5 JP2016538101A JP2016538101A JP2017500305A5 JP 2017500305 A5 JP2017500305 A5 JP 2017500305A5 JP 2016538101 A JP2016538101 A JP 2016538101A JP 2016538101 A JP2016538101 A JP 2016538101A JP 2017500305 A5 JP2017500305 A5 JP 2017500305A5
Authority
JP
Japan
Prior art keywords
composition
seq
tarp
composition according
overlapping
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016538101A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017500305A (ja
JP6758185B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/070144 external-priority patent/WO2015089469A1/en
Publication of JP2017500305A publication Critical patent/JP2017500305A/ja
Publication of JP2017500305A5 publication Critical patent/JP2017500305A5/ja
Application granted granted Critical
Publication of JP6758185B2 publication Critical patent/JP6758185B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016538101A 2013-12-13 2014-12-12 マルチエピトープtarpペプチドワクチンおよびその使用 Active JP6758185B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361915948P 2013-12-13 2013-12-13
US61/915,948 2013-12-13
PCT/US2014/070144 WO2015089469A1 (en) 2013-12-13 2014-12-12 Multi-epitope tarp peptide vaccine and uses thereof

Publications (3)

Publication Number Publication Date
JP2017500305A JP2017500305A (ja) 2017-01-05
JP2017500305A5 true JP2017500305A5 (enExample) 2018-01-18
JP6758185B2 JP6758185B2 (ja) 2020-09-23

Family

ID=52432905

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016538101A Active JP6758185B2 (ja) 2013-12-13 2014-12-12 マルチエピトープtarpペプチドワクチンおよびその使用

Country Status (7)

Country Link
US (1) US10286050B2 (enExample)
EP (1) EP3079716B1 (enExample)
JP (1) JP6758185B2 (enExample)
AU (1) AU2014361788B2 (enExample)
CA (1) CA2932248C (enExample)
DK (1) DK3079716T3 (enExample)
WO (1) WO2015089469A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11266726B2 (en) 2015-10-30 2022-03-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions and methods for the treatment of HER2-expressing solid tumors
WO2019113200A1 (en) 2017-12-05 2019-06-13 Pds Biotechnology Corporation Methods and compositions comprising cationic lipids for stimulating type 1 interferon genes
JP2025534757A (ja) * 2022-10-17 2025-10-17 ピーディーエス バイオテクノロジー コーポレイション 新規のHLA非拘束性T細胞用TCRγ代替リーディングフレームタンパク質(TARP)組成物およびその使用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5270202A (en) 1989-11-03 1993-12-14 Syamal Raychaudhuri Anti-idiotypic antibodies to human melanoma-associated proteoglycan antigen
US5709860A (en) 1991-07-25 1998-01-20 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
RO116459B1 (ro) 1991-07-25 2001-02-28 Idec Pharma Corp Compozitie imunogena
US5643578A (en) 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
US5662907A (en) 1992-08-07 1997-09-02 Cytel Corporation Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes
EP0671926B1 (en) 1992-08-11 2002-11-13 President And Fellows Of Harvard College Immunomodulatory peptides
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
EP1167379A3 (en) 1994-07-15 2004-09-08 University Of Iowa Research Foundation Immunomodulatory oligonucleotides
WO1998037919A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
EP1003531B1 (en) 1997-05-20 2007-08-22 Ottawa Health Research Institute Processes for preparing nucleic acid constructs
AU760549B2 (en) 1998-04-03 2003-05-15 University Of Iowa Research Foundation, The Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
AU781925B2 (en) 1999-07-13 2005-06-23 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The T-cell receptor gamma alternate reading frame protein, (TARP) and uses thereof
SE9903031D0 (sv) * 1999-08-27 1999-08-27 Eurodiagnostica Ab Peptide mixture and vaccine against a chronic viral infection
WO2004002415A2 (en) * 2002-06-27 2004-01-08 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating a cytotoxic t lymphocyte immune response
US7541035B2 (en) 2003-06-05 2009-06-02 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Immunogenic peptides for the treatment of prostate and breast cancer
EP2040745B1 (en) 2006-06-28 2012-12-05 Statens Serum Institut Expanding the t cell repertoire to include subdominant epitopes by vaccination with antigens delivered as protein fragments or peptide cocktails

Similar Documents

Publication Publication Date Title
KR102308798B1 (ko) 다양한 암의 면역요법 치료에서의 사용을 위한 펩티드, 펩티드의 조합 및 골격
PH12016500949B1 (en) Novel immunotherapy against several tumors including gastrointestinal and gastric cancer
JP2018510215A5 (enExample)
JP2018509936A5 (enExample)
KR20180085725A (ko) 다양한 암에 대한 면역요법에서의 사용을 위한 신규 펩티드 및 펩티드의 조합
KR20180111998A (ko) 비호지킨 림프종 및 기타 암에 대한 면역요법에서의 사용을 위한 신규 펩티드 및 펩티드의 조합
EA201071297A1 (ru) Новые и действенные пептиды мнс ii класса, полученные из сурвивина
EP3545965A3 (en) Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers
US20250312428A1 (en) Heterologous Prime Boost Vaccine
PE20181897A1 (es) Inmunoterapia contra el melanoma y otros tipos de cancer
JP6406647B2 (ja) 細胞性免疫誘導ワクチン
JP2016511221A5 (enExample)
JP2014519311A5 (enExample)
JP2017500305A5 (enExample)
JP2015529219A5 (enExample)
JP2018528960A5 (enExample)
JP2014506114A5 (enExample)
RU2015126849A (ru) Пептиды sema5в и вакцины, содержащие эти пептиды
NZ746513A (en) Novel peptides and combination of peptides for use in immunotherapy against various tumors
MY198397A (en) Novel Immunotherapy Against Several Tumors Including Gastrointestinal And Gastric Cancer
MY194244A (en) Novel Immunotherapy Against Several Tumors, Such as Lung Cancer, Including Nsclc
MY194653A (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
MY193910A (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
EA202090822A2 (ru) Новый метод иммунотерапии нескольких видов опухолей, таких как рак легкого, включая нмрл
TH154722A (th) องค์ประกอบของเพปไทด์ที่มีส่วนร่วมกับเนื้องอกและวัคซีนต้านมะเร็งที่สัมพันธ์กันสำหรับการบำบัดของมะเร็งกระเพาะอาหารและมะเร็งอื่นๆ